{"product_id":"bngo-vrio-analysis","title":"Bionano Genomics, Inc. (BNGO): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Bionano Genomics, Inc. (BNGO)'s market position starts here: this concise VRIO analysis cuts straight to the chase, examining if its core assets are truly Valuable, Rare, Inimitable, and Organized to forge a sustainable competitive edge. Discover the distilled summary of what truly drives Bionano Genomics, Inc. (BNGO)'s performance and why it matters - read on to see the full breakdown!\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBionano Genomics, Inc. (BNGO) - VRIO Analysis: Optical Genome Mapping (OGM) Technology Platform\n\u003c\/h2\u003e\n\n\u003cp\u003eThe Optical Genome Mapping (OGM) platform is Bionano Genomics, Inc.’s core asset, offering a single-assay method for structural variant detection that aims to supersede older, multi-step processes. The technology’s value proposition is supported by growing scientific validation, evidenced by 97 new peer-reviewed publications in the third quarter of 2025 alone.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Single-Assay Comprehensiveness\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe OGM technology enables comprehensive structural variant detection in one test. This consolidation helps researchers and clinicians address complex genetic questions faster than traditional methods. The shift in revenue mix toward this platform is clear, as consumables and software revenue grew 15% year-over-year in Q3 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Unique High-Resolution Analysis\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCurrently, the specific approach for high-resolution, whole-genome structural analysis using OGM remains distinct in the market. While competitors exist in the broader genomics space, OGM’s specific methodology for visualizing large structural variants is not easily replicated by existing sequencing or array technologies. This uniqueness is vital for its current market positioning.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Protected by Intellectual Property\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eImitation is difficult because the core technology relies on complex, proprietary methods, including nanochannel fabrication and labeling, which are protected by patents. For example, patents covering methods for using nanochannel arrays were issued as recently as April 2022, reinforcing the IP moat around the core mechanism.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Developing Commercial Scale\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company is structured to commercialize the Saphyr and Stratus systems, but achieving full scale is still a work in progress. The installed base reached 384 systems by the end of Q3 2025, a modest 4% year-over-year increase, with only 7 net new systems added that quarter. The focus is clearly on driving utilization, as shown by the 46% non-GAAP gross margin in Q3 2025, up from 26% the prior year, indicating better operational leverage from existing assets. The company ended Q3 2025 with $31.8 million in cash and equivalents after raising $10 million in September 2025.\u003c\/p\u003e\n\n\u003cp\u003eHere’s a quick look at the Q3 2025 operational snapshot:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eComparison\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp 21% year-over-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFlow Cells Sold\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8,390\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp 7% year-over-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled Base (Systems)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e384\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNet increase of 3 systems in Q3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-GAAP Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from 26% in Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2025 Revenue Guidance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26.0 to $30.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReiterated guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary Status\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe advantage is currently temporary. While patents provide near-term protection, the high-stakes nature of genomic technology means a competitor could develop a superior, faster, or cheaper platform that leapfrogs OGM in the long run. Bionano Genomics, Inc. must continue to innovate rapidly to maintain its lead, especially as it works toward broader clinical reimbursement.\u003c\/p\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBionano Genomics, Inc. (BNGO) - VRIO Analysis: High-Margin Consumables \u0026amp; Software Revenue Stream\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue: Drives predictable, recurring revenue, which is crucial for financial stability\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nConsumables and software revenues increased by \u003cstrong\u003e15%\u003c\/strong\u003e in Q3 2025 compared to Q3 2024. These categories represented \u003cstrong\u003e72%\u003c\/strong\u003e of the product mix in Q3 2025.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Value\u003c\/td\u003e\n\u003ctd\u003eComparison\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp 21% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables \u0026amp; Software Revenue Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNon-GAAP 46%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$31.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eRarity: Moderate; many med-tech firms have razor-and-blade models, but Bionano's specific flowcell sales are tied to a unique platform.\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe specific nanochannel array flowcells sold were \u003cstrong\u003e8,390\u003c\/strong\u003e units in Q3 2025, representing a \u003cstrong\u003e7%\u003c\/strong\u003e increase year-over-year.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eImitability: Moderate; competitors can develop similar consumables if they replicate the OGM system's core function.\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe installed base reached \u003cstrong\u003e384\u003c\/strong\u003e Optical Genome Mapping (OGM) systems at the end of Q3 2025, a \u003cstrong\u003e4%\u003c\/strong\u003e increase over the prior year.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eOrganization: High; management's strategic pivot explicitly focuses on driving utilization of these high-margin items, showing strong alignment.\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe strategic focus on utilization is evidenced by operational metrics:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFY 2025 Revenue Guidance reiterated at \u003cstrong\u003e$26.0 to $30.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ4 2025 Revenue Guidance initiated at \u003cstrong\u003e$7.5 to $7.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGAAP Operating Expenses reduced to \u003cstrong\u003e$11.9 million\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eNon-GAAP Operating Expense reduced to \u003cstrong\u003e$9.7 million\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Sustained; the shift to a recurring revenue focus, evidenced by 15% consumables revenue growth in Q3 2025, creates a stickier customer base.\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe company raised \u003cstrong\u003e$10 million\u003c\/strong\u003e in a September public offering.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBionano Genomics, Inc. (BNGO) - VRIO Analysis: Installed Base of OGM Systems\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eInstalled Base of OGM Systems\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eValue: Represents the installed customer base ready to purchase high-margin flowcells and software licenses. The base stood at \u003cstrong\u003e384 systems\u003c\/strong\u003e by end of Q3 2025.\u003c\/p\u003e\n\u003cp\u003eRarity: Low; capital equipment sales are common, but the installed base is relatively small compared to established sequencing platforms.\u003c\/p\u003e\n\u003cp\u003eImitability: Low; competitors can place their own capital equipment, though it takes time and capital to build this base.\u003c\/p\u003e\n\u003cp\u003eOrganization: Moderate; the focus is now on utilization rather than new placements, suggesting the organization is adapting to maximize this asset.\u003c\/p\u003e\n\u003cp\u003eCompetitive Advantage: Temporary; the value is only sustained if the installed base is actively using the systems to buy consumables.\u003c\/p\u003e\n\u003cp\u003eThe utilization and growth metrics supporting the installed base value for Q3 2025 are detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Value\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Installed OGM Systems (End of Q3)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e384 systems\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4%\u003c\/strong\u003e increase over Q3 2024 (368 systems)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew OGM Systems Installed (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7 systems\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNanochannel Array Flowcells Sold\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8,390 flowcells\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e7%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables and Software Revenues\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$5.3 million\u003c\/strong\u003e (of $7.4M total revenue)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e15%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstrument Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e21%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther operational data points include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company expects new OGM system installations to surpass \u003cstrong\u003e25\u003c\/strong\u003e for the full year 2025.\u003c\/li\u003e\n\u003cli\u003eThe installed base growth represented a \u003cstrong\u003e4%\u003c\/strong\u003e increase over the 368 installed systems reported at the end of the third quarter of 2024.\u003c\/li\u003e\n\u003cli\u003eNon-GAAP gross margin reached \u003cstrong\u003e46%\u003c\/strong\u003e in Q3 2025, compared to \u003cstrong\u003e26%\u003c\/strong\u003e for the third quarter of 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eBionano Genomics, Inc. (BNGO) - VRIO Analysis: Improved Non-GAAP Gross Margin \u0026amp; Cost Structure\n\u003c\/h2\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eSignificant financial health improvement demonstrated by Non-GAAP Gross Margin reaching \u003cstrong\u003e46%\u003c\/strong\u003e in Q3 2025, a substantial increase from \u003cstrong\u003e26%\u003c\/strong\u003e in Q3 2024.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eLow; margin improvement is expected as a company matures and shifts focus to consumables.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eLow; this is a result of internal operational discipline and strategic mix-shift, which is imitable through focused management.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh; the \u003cstrong\u003e66%\u003c\/strong\u003e reduction in operating expenses to \u003cstrong\u003e$11.9 million\u003c\/strong\u003e in Q3 2025 shows management is highly organized around cost control. The non-GAAP operating expenses were \u003cstrong\u003e$9.7 million\u003c\/strong\u003e, representing a \u003cstrong\u003e40%\u003c\/strong\u003e year-over-year reduction.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary; while impressive now, this margin level must be maintained against potential future price erosion or rising input costs.\u003c\/p\u003e\n\n\u003cp\u003eThe strategic shift toward higher-margin components is evidenced by the following operational and financial metrics for the three-month period ended September 30, 2025:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Value\u003c\/th\u003e\n\u003cth\u003eQ3 2024 Value\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Change\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-GAAP Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e+\u003cstrong\u003e20\u003c\/strong\u003e percentage points\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e21%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables and Software Revenue\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e15%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNanochannel Array Flowcells Sold\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8,390\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7,835\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e7%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses (Reported)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e66%\u003c\/strong\u003e reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Installed Base (OGM Systems)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e384\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e368\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe increased utilization and revenue mix shift are further detailed:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eConsumables and software represented \u003cstrong\u003e72%\u003c\/strong\u003e of the total product mix in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eThe cumulative number of clinical research genomes published on OGM is nearly \u003cstrong\u003e11,500\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThere were \u003cstrong\u003e7\u003c\/strong\u003e new OGM system installations in Q3 2025, with \u003cstrong\u003e1\u003c\/strong\u003e system brought back.\u003c\/li\u003e\n\u003cli\u003eYear-to-date through September 30, 2025, \u003cstrong\u003e23\u003c\/strong\u003e new systems were installed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eBionano Genomics, Inc. (BNGO) - VRIO Analysis: Scientific Publication \u0026amp; Validation Momentum\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Builds credibility and drives adoption by providing peer-reviewed evidence of OGM utility across cancer and genetic disorders. \u003cstrong\u003e97\u003c\/strong\u003e new publications in Q3 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; high publication volume is rare for a company of this size, showing strong engagement from the research community.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; competitors can fund their own research and publications, but Bionano has a head start in this specific area.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company actively highlights and leverages these studies in its commercial and reimbursement efforts.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; the cumulative body of evidence and the network effect of published research create a high barrier to entry for new methods.\u003c\/p\u003e\n\n\u003cp\u003eThe momentum in scientific validation is directly supported by key operational and financial metrics from Q3 2025:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Value\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Change\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e21%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables \u0026amp; Software Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e15%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFlowcells Sold\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e8,390\u003c\/strong\u003e units\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e7%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Installed Base (OGM Systems)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e384\u003c\/strong\u003e systems\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-GAAP Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from \u003cstrong\u003e26%\u003c\/strong\u003e in Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-GAAP Operating Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e40%\u003c\/strong\u003e decrease\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe publication momentum is quantified by the following research output statistics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e97\u003c\/strong\u003e new peer-reviewed publications in Q3 2025, representing a \u003cstrong\u003e10%\u003c\/strong\u003e growth over Q3 2024.\u003c\/li\u003e\n\u003cli\u003eA cumulative total of nearly \u003cstrong\u003e11,500\u003c\/strong\u003e clinical research genomes published using OGM.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e841\u003c\/strong\u003e human clinical research genomes published using OGM during Q3 2025, an \u003cstrong\u003e84%\u003c\/strong\u003e increase compared to Q3 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis validation is being monetized through regulatory progress, including a preliminary payment determination from CMS for a Category I CPT code of \u003cstrong\u003e$1,263.53\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBionano Genomics, Inc. (BNGO) - VRIO Analysis: Intellectual Property Portfolio (Patents)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eIntellectual Property Portfolio (Patents)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eProtects the core OGM methods, nanochannel fabrication, and sample processing workflows from direct copying. The portfolio includes patents covering the core technology of confining and linearizing ultra-long DNA and other macromolecules in parallel nanochannel arrays, and the detection of feature-specific sequence or genomic labels on those molecules. Specific patents cover methods for the analysis of small nucleic acid fragments in nanochannel arrays, such as US Patent No. \u003cstrong\u003e11,359,244\u003c\/strong\u003e issued on June 14, 2022.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eModerate; having a portfolio of patents covering core technology is standard but necessary in this space. BioNano Genomics' grant share as of June 2024 was reported at \u003cstrong\u003e33%\u003c\/strong\u003e. Patents related to industrial automation, genomics, and nanomedicine lead the portfolio.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eLow; patents provide legal, but not necessarily practical, barriers; competitors may design around them. The company's patenting activity in Q2 2024 showed the United States (US) Patent Office dominating with \u003cstrong\u003e100%\u003c\/strong\u003e of its grants in that period.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eModerate; the IP is managed, but its direct impact on near-term revenue is indirect, relying on the commercial team to enforce it. Full year 2024 GAAP operating expense, which includes legal and IP management overhead, was \u003cstrong\u003e$104.4 million\u003c\/strong\u003e. The company's General Counsel oversees all legal operations, including intellectual property.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eTemporary; patent life is finite, and the true advantage lies in the application of the IP, not just its existence. The application of the IP is evidenced by product adoption metrics.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOGM Installed Base (End of Year)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e371\u003c\/strong\u003e systems\u003c\/td\u003e\n\u003ctd\u003eEnd of 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFlowcells Sold\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30,307\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublished Human Clinical Samples\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e8,800\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of End of 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Grant Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e33%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted Non-GAAP R\u0026amp;D Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8,608,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe scope of protection afforded by the intellectual property portfolio includes specific technological advancements:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMethods for the analysis of small nucleic acid fragments in nanochannel arrays, potentially supporting applications in non-invasive prenatal testing (NIPT) or circulating tumor DNA (ctDNA) in oncology.\u003c\/li\u003e\n\u003cli\u003eMethods of identifying genomic sequences or structural genomic variants (SV) by linearizing target DNA molecules through a series of nanochannels (e.g., US Patent No. \u003cstrong\u003e11,292,713\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eA novel apparatus and method for using a light source to minimize aggregation of biopolymers in or around a nanochannel (US Patent No. \u003cstrong\u003e11,291,999\u003c\/strong\u003e), enabling multiple cycles of DNA loading, imaging, clearing, and reloading.\u003c\/li\u003e\n\u003cli\u003ePatents directed to methods of fabricating nanochannel devices.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eBionano Genomics, Inc. (BNGO) - VRIO Analysis: CPT Code Progress for Reimbursement\n\u003c\/h2\u003e\n\u003cp\u003eCPT Code Progress for Reimbursement\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eValue: The preliminary payment determination for the Category I CPT code by CMS is a critical step toward routine clinical adoption and payer coverage.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eBionano Laboratories has secured two Category I CPT codes for Optical Genome Mapping (OGM) technology: 81195 for hematologic malignancy analysis and 81354 for constitutional genetic disease analysis.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCPT Code\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eInitial CMS Payment Determination (Effective Jan 1, 2025\/2026)\u003c\/th\u003e\n\u003cth\u003eComparison to Microarray Codes\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e81195\u003c\/td\u003e\n\u003ctd\u003eHematologic Malignancy\u003c\/td\u003e\n\u003ctd\u003ePreliminary: \u003cstrong\u003e$1,263.53\u003c\/strong\u003e (Effective Jan 1, 2025)\u003c\/td\u003e\n\u003ctd\u003eN\/A (Reconsidered)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e81354\u003c\/td\u003e\n\u003ctd\u003eConstitutional Genetic Disease\u003c\/td\u003e\n\u003ctd\u003ePreliminary: \u003cstrong\u003e$1,263.53\u003c\/strong\u003e (Effective Jan 1, 2026)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$363.53 higher\u003c\/strong\u003e than code 81228 ($900); \u003cstrong\u003e$103.53 higher\u003c\/strong\u003e than code 81229 ($1,160)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe payment for code 81195 was subsequently increased to \u003cstrong\u003e$1,853.22\u003c\/strong\u003e for the 2026 Clinical Lab Fee Schedule, representing a \u003cstrong\u003e47% increase\u003c\/strong\u003e from the initial determination.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity: High; achieving a Category I CPT code determination is a significant regulatory and market milestone in diagnostics.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe establishment of a Category I CPT code signifies meeting the rigorous standards of acceptance by the medical community, contrasting with a Category III code for emerging technologies.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe CDLT committee voted unanimously, 10-0 with no abstentions, in favor of the crosswalk supporting the higher payment for code 81195.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eImitability: Very High; this process is specific to the US regulatory environment and the company's specific technology.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe process involves the American Medical Association (AMA) editorial panel and Centers for Medicare \u0026amp; Medicaid Services (CMS) review specific to the Optical Genome Mapping (OGM) technology.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization: High; management is actively building support for reimbursement, making this a key organizational focus.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eManagement has focused on securing these codes to strengthen reimbursement support.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBionano raised net proceeds of \u003cstrong\u003e$3.2 million\u003c\/strong\u003e through ATM sales during the first quarter of 2025.\u003c\/li\u003e\n\u003cli\u003eThe company maintained an installed base of 378 optical genome mapping systems as of Q2 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Sustained; once a CPT code is established and reimbursement pathways are built, it creates a massive hurdle for any new technology trying to enter the same clinical workflow.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe established codes provide clear reimbursement pathways for OGM-based LDTs, such as OGM-Dx™ HemeOne, OGM-Dx™ Postnatal Whole Genome SV, and OGM-Dx™ Prenatal Whole Genome SV.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBionano Genomics, Inc. (BNGO) - VRIO Analysis: Integrated Genomic Data Analysis Software Suite (VIA\/Solve)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Enhances the utility of the OGM data, making analysis faster and more accurate, and is key to driving software revenue.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe strategic focus is on driving utilization of OGM systems and \u003cstrong\u003eVIA™ software\u003c\/strong\u003e among routine users.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCore product and software sales for Q3 2024 were \u003cstrong\u003e$6.6 million\u003c\/strong\u003e, offset by a \u003cstrong\u003e$0.5 million\u003c\/strong\u003e write-down of aged receivables.\u003c\/li\u003e\n\u003cli\u003eConsumables and software revenues increased \u003cstrong\u003e15%\u003c\/strong\u003e year-over-year in Q3 2025 compared to Q3 2024.\u003c\/li\u003e\n\u003cli\u003eThe company announced upgrades to \u003cstrong\u003eVIA and Solve™ software\u003c\/strong\u003e to make analysis easier, faster, and more accurate.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate; platform-agnostic software solutions are becoming more common, but Bionano's integration with its own OGM data is proprietary.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe installed base of OGM systems underpins the proprietary data ecosystem for VIA\/Solve.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal installed base of Optical Genome Mapping (OGM) systems was \u003cstrong\u003e368\u003c\/strong\u003e as of the end of Q3 2024.\u003c\/li\u003e\n\u003cli\u003eThe installed base reached \u003cstrong\u003e384\u003c\/strong\u003e at the end of Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Moderate; competitors can develop comparable analysis tools, but integrating them seamlessly with OGM data takes time.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe time required for competitors to match the seamless integration of analysis tools with OGM data represents a barrier.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: High; upgrades to VIA and Solve software are a stated part of the strategy to drive utilization among existing users.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organizational structure supports the shift to a utilization-driven model.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company executed a strategic shift to focus on the base of routine users of OGM and \u003cstrong\u003eVIA™ software\u003c\/strong\u003e as primary revenue drivers in Q1 2025.\u003c\/li\u003e\n\u003cli\u003eNon-GAAP operating expenses were reduced by \u003cstrong\u003e40%\u003c\/strong\u003e to \u003cstrong\u003e$9.7 million\u003c\/strong\u003e in Q3 2025, compared to \u003cstrong\u003e$16.1 million\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eGAAP operating expenses decreased by \u003cstrong\u003e66%\u003c\/strong\u003e to \u003cstrong\u003e$11.9 million\u003c\/strong\u003e in Q3 2025 from Q3 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary; software is often the easiest component to replicate or surpass with newer AI\/ML tools from other firms.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKey Statistical and Financial Data Points for OGM\/Software Utilization Context\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOGM System Installed Base\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e368\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e384\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNanochannel Array Flowcells Sold\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7,835\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8,390\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-GAAP Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-GAAP Operating Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eBionano Genomics, Inc. (BNGO) - VRIO Analysis: Management's Strategic Focus on Routine User Adoption\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This focus is the engine behind the improved gross margin and recurring revenue, stabilizing the business model.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNon-GAAP Gross Margin improved from 26% in Q3 2024 to 46% in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eConsumables and software sales grew 15% year-over-year in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; every company wants routine users, but Bionano's decisive pivot to this focus in 2025 is a recent, notable organizational choice.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe strategic shift was explicitly noted as occurring 'Over the last year' leading up to Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the strategy itself is clear, but the execution - reducing operating expenses by 66% while maintaining R\u0026amp;D - is hard to copy quickly.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNon-GAAP Operating Expenses were reduced by 66% to $11.9 million in Q3 2025, compared to $35.5 million GAAP Operating Expenses in Q3 2024 (or a 40% reduction in Non-GAAP OpEx from $16.1 million in Q3 2024 to $9.7 million in Q3 2025).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the CEO's commentary confirms this is the central organizing principle for sales, support, and finance.\u003c\/p\u003e\n\u003cp\u003eManagement's strategy is executed against 4 strategic pillars:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSupporting and sustaining the installed base of routine OGM and VIA software users.\u003c\/li\u003e\n\u003cli\u003eAiming to drive utilization through the adoption of software across routine OGM users.\u003c\/li\u003e\n\u003cli\u003eBuilding support needed for optical genome mapping reimbursement and inclusion in medical society guidelines.\u003c\/li\u003e\n\u003cli\u003eIntending to improve profitability and scalability with lower costs and higher volumes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; if this focus successfully drives utilization and profitability, it becomes a self-reinforcing, sustained advantage over competitors stuck on a pure capital equipment model.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2024 (Reference)\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 (Current)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-GAAP Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-GAAP Operating Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOGM Installed Base (End of Period)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e368\u003c\/strong\u003e systems\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e384\u003c\/strong\u003e systems\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNanochannel Array Flowcells Sold\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6,176\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8,390\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Restricted Cash\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$23.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$31.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516126650517,"sku":"bngo-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/bngo-vrio-analysis.png?v=1740153368","url":"https:\/\/dcf-model.com\/pt\/products\/bngo-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}